EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities

Anna Maria Frustaci iD, Marina Deodato, Giulia Zamprogna, Roberto Cairoli iD, Marco Montillo, Alessandra Tedeschi

Cancers · 27.02.2023 · 15 (5) · 1504

DOI: 10.3390/cancers15051504 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 27.02.2023. Verfasst von Anna Maria Frustaci und 5 weiteren Autor:innen. Beteiligte Einrichtung: ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Piazza Ospedale Maggiore 3, 20162 Milano, Italy. Die Arbeit wurde bisher 50-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ibrutinib revolutionized the CLL treatment approach and prognosis demonstrating its efficacy and safety even at extended follow-up. During the last few years, several next-generation inhibitors have been developed to overcome the occurrence of toxicity or resistance in patients on continuous treatment. In a head-to-head comparison of two phase III trials, both acalabrutinib and zanubrutinib demonstrated a lower incidence of adverse events in respect to ibrutinib. Nevertheless, resistance mutations remain a concern with continuous therapy and were demonstrated with both first- and next-generation covalent inhibitors. Reversible inhibitors showed efficacy independently of previous treatment and the presence of BTK mutations. Other strategies are currently under development in CLL, especially for high-risk patients, and include BTK inhibitor combinations with BCl2 inhibitors with or without anti-CD20 monoclonal antibodies. Finally, new mechanisms for BTK inhibition are under investigations in patients progressing with both covalent and non-covalent BTK and BCl2 inhibitors. Here we summarize and discuss results from main experiences on irreversible and reversable BTK inhibitors in CLL.

Schlagwörter

Stichwörter der Autor:innen

acalabrutinibpirtobrutinibzanubrutinib

Autor:innen und Institutionen

  • ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Piazza Ospedale Maggiore 3, 20162 Milano, Italy.

ORCID-Profile: Anna Maria Frustaci, Roberto Cairoli

Zitieren

APA

Frustaci, A. M., Deodato, M., Zamprogna, G., Cairoli, R., Montillo, M., & Tedeschi, A. (2023). Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers, 15(5), 1504. https://doi.org/10.3390/cancers15051504

Vancouver

Frustaci AM, Deodato M, Zamprogna G, Cairoli R, Montillo M, Tedeschi A. Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities. Cancers. 2023;15(5):1504. doi:10.3390/cancers15051504

BibTeX
@article{Frustaci2023,
  author = {Frustaci, Anna Maria and Deodato, Marina and Zamprogna, Giulia and Cairoli, Roberto and Montillo, Marco and Tedeschi, Alessandra},
  title = {Next Generation BTK Inhibitors in CLL: Evolving Challenges and New Opportunities},
  journal = {Cancers},
  year = {2023},
  volume = {15},
  number = {5},
  pages = {1504},
  doi = {10.3390/cancers15051504}
}
Kostenlos starten →